s-c-s/iStock via Getty Images
- Odyssey Health (OTCPK:ODYY) said it had completed the study of all cohorts for its Phase I Single Ascending Dosing and Multiple Ascending Dosing clinical trial of PRV-002, its drug to treat concussion.
- (OTCPK:ODYY) is up ~11%.
- The company said it is working with the United States military to identify sites for the Phase II trials. Concussions in the armed forces are a serious issue.